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ABSTRACT
Chromatin undergoes structural changes in response to extracellular and 
environmental signals. We observed changes in nuclear morphology in cancer tissue 
biopsied after chemotherapy and hypothesised that these DNA damage-induced 
changes are mediated by histone deacetylases (HDACs). Nuclear morphological 
changes in cell lines (PE01 and PE04 models) and a xenograft model (OV1002) 
were measured in response to platinum chemotherapy by image analysis of nuclear 
texture. HDAC2 expression increased in PEO1 cells treated with cisplatin at 24h, 
which was accompanied by increased expression of heterochromatin protein 1 (HP1). 
HDAC2 and HP1 expression were also increased after carboplatin treatment in the 
OV1002 carboplatin-sensitive xenograft model but not in the insensitive HOX424 
model. Expression of DNA damage response pathways (pBRCA1, γH2AX, pATM, pATR) 
showed time-dependent changes after cisplatin treatment. HDAC2 knockdown by 
siRNA reduced HP1 expression, induced DNA double strand breaks (DSB) measured 
by γH2AX, and interfered with the activation of DNA damage response induced by 
cisplatin. Furthermore, HDAC2 depletion affected γH2AX foci formation, cell cycle 
distribution, and apoptosis triggered by cisplatin, and was additive to the inhibitory 
effect of cisplatin in cell lines. By inhibiting expression of HDAC2, reversible alterations 
in chromatin patterns during cisplatin treatment were observed. These results 
demonstrate quantifiable alterations in nuclear morphology after chemotherapy, 
and implicate HDAC2 in higher order chromatin changes and cellular DNA damage 
responses in ovarian cancer cells in vitro and in vivo.
INTRODUCTION
Chromatin structure is dynamic, and changes occur 
in response to extracellular and environmental signals 
[1]. Histone tail acetylation is an important chromatin 
modification that alters DNA accessibility to regulating 
enzymes by transforming chromatin from a compact to 
relaxed structure that is permissive of gene expression [2, 
3]. The balance between histone acetyltransferase (HAT) 
and histone deacetylase (HDAC) activities ultimately 
determines acetylation status [4]. Histone acetylation is 
involved with cellular differentiation, mitosis and meiosis, 
DNA transcriptional regulation, DNA damage, DNA 
replication, and circadian rhythms [5, 6, 7, 8].
Mammalian HDACs are grouped into four classes 
based on structural homology, enzymatic activity, and 
cellular localisation [9, 10, 11, 12]. Class I HDACs 
(HDAC 1, 2, 3, and 8) are mainly nuclear, and they 
interact with histones and other proteins [13, 14], while 
class II HDACs (HDAC 4, 5, 6, 7, 9, and 10) are tissue-
specific and can be both nuclear and cytoplasmic [13]; 
the majority of HDAC inhibitors inhibit both class I and 
class II enzymes [15, 13]. Class III HDACs, namely 
sirtuins (SIRTs1 – 7; silent information regulators), are 
unresponsive to most HDAC inhibitors but require the 
cofactor NAD+. Finally, the class IV HDAC, HDAC11, is 
expressed in the nucleus and shares homology with class I 
and class II HDACs [15, 16].
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HAT and HDAC activity can be altered by 
mutation, overexpression, or translocation, disrupting 
the acetylation-deacetylation balance and consequently 
contributing to cancer hallmarks; these epigenetic changes 
have been observed in leukaemia and prostate, breast, 
colorectal, and ovarian cancers [17, 13]. Acetylation 
changes are thought to participate in carcinogenesis 
by silencing tumor suppressor gene promoters, such as 
p21, [18, 19], activation of repressed genes, or abnormal 
recruitment of HATs or HDACs [13].
The heterochromatin protein 1 (HP1) protein 
family plays various roles in establishing and maintaining 
heterochromatin (tightly-packed DNA) structure, thereby 
repressing transcription [20]. HP1 overexpression can 
cause global gene repression and chromatin condensation 
[21, 22]. The three human HP1 isoforms, HP1α, HP1β, 
and HP1γ, share functions and localise to chromatin with 
incomplete overlap [23], differentially localising to centric 
heterochromatin, telomeres, and specific euchromatic 
sites [24]. Alterations in HP protein expression have been 
identified in some cancers including ovarian [25], breast 
[26], and colorectal cancer [27].
We have observed changes in nuclear structure 
in clinical samples of cancer tissue after treatment with 
chemotherapy and radiotherapy. Since structure dictates 
gene expression and, therefore, function, we sought 
to investigate this phenomenon to better understand 
therapeutic responses. We hypothesised that nuclear 
morphological changes in cancer in response to DNA 
damage are mediated by HDACs and are associated 
with changes in HP1 protein expression and/or nuclear 
distribution. Initial studies indicated changes in expression 
of HDAC2, therefore, we explored whether HDAC2 
mediated response to injury and might act as a resistance 
factor to DNA-damaging therapy.
RESULTS
Nuclear structure changes after chemotherapy 
or radiotherapy in ovarian cancer cells
Preliminary observations by light microscopy 
suggested that nuclear morphology was different in 
clinical tumors after treatment with chemotherapy and 
radiotherapy (Figure 1). To explore this phenomenon 
further, chromatin patterns were quantified by nuclear 
texture image analysis in an ovarian cancer cell line 
model. Texture features were regarded as positively 
or negatively associated with chromatin patterns 
(homogeneity, heterogeneity, and contrast) as previously 
described [28, 29]. Five parameters associated with 
texture were obtained: angular second moment (ASM), 
correlation, entropy, inverse different moment (IDM) 
and contrast. ASM is a strong measure of uniformity 
or smoothness associated with overall homogeneity of 
chromatin patterns. Correlation calculates the grey-level 
linear dependency of the image and correlates negatively 
with the heterogeneity of chromatin patterns. Entropy 
measures pattern disorder and is negatively correlated with 
homogeneity. Inverse different moment (IDM) measures 
the local variability and intensity of a region of interest 
(ROI) and is affected by image homogeneity, with non-
homogeneous areas normally resulting in low IDM values; 
thus, it is described as the ‘contrast’ of chromatin patterns.
PE01 ovarian cancer cells [30] grown on coverslips 
were treated with cisplatin or ionising radiation and 
incubated for 0h, 6h, 12h and 24h. After 24 h treatment 
with 6 μM cisplatin or 6 Gy radiation, all five image 
texture parameters measured changed compared to 
untreated controls; observations were similar for both 
cisplatin and radiation. ASM, correlation, and IDM 
Figure 1. Nuclear morphology changes in different clinical and experimental settings. Similar nuclear texture changes 
occur in: A. ovarian tumors after chemotherapy; B. breast tumors after neoadjuvant therapy; C. colorectal tumors after radiotherapy; 
D. ovarian tumor xenografts after carboplatin treatment; and E. the ovarian cancer cell line PEO1 after cisplatin treatment. A-D are 
formalin-fixed, paraffin embedded sections cut from tumor samples and stained with H&E. E shows PEO1 cell cytospins using the Feulgen 
nuclear stain.
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decreased after cisplatin/radiation treatment by 20%/23%, 
25%/49%, and 15%/11%, respectively, while entropy 
and contrast increased by 6%/8% and 40%/120%. The 
heterogeneity and contrast of chromatin increased and the 
homogeneity decreased in cell nuclei after DNA damage-
inducing treatment with cisplatin and radiation, consistent 
with the observations made by light microscopy.
Measurement of nuclear texture changes in 
response to carboplatin in vivo
We next sought to establish whether similar nuclear 
changes occur in vivo using a platinum-sensitive OV1002 
patient-derived ovarian cancer xenograft model [31]. 
Carboplatin, a cisplatin analogue, was used as this drug 
is commonly used clinically. After a single treatment with 
carboplatin, ovarian cancer xenografts were collected 
on days 0, 1, 2, 4, 7, and 14. Haematoxylin and eosin 
(H&E) staining and light microscopy indicated similar 
morphological changes to those seen in vitro (Figure 
1). Untreated tumors tended to have strongly stained 
and homogeneous nuclei, while nuclei after carboplatin 
treatment had more lightly stained nuclei and greater 
heterogeneity (Figure 2B). When nuclear texture was 
analysed by image analysis, texture parameters were 
different in samples after carboplatin treatment compared 
Figure 2. Alterations in nuclear texture in vitro and in vivo after treatment with platinum drugs or radiotherapy. 
A. Changes in nuclear texture in PEO1 cells after irradiation or cisplatin treatment. PEO1 cells were grown on coverslips and treated with 
ionising radiation (6Gy) or cisplatin (6uM) for 24h, and nuclei were stained with DAPI for visualisation using a fluorescence microscope. 
At least 100 nuclei were included in each experiment. Nuclear texture was analysed by measuring five texture parameters (angular second 
moment, correlation, entropy, inverse different moment, and contrast) using Image J software. Data are presented as the average change 
(%) in the treated group for each parameter over the control group. B. Representative images from H&E-stained OV1002 ovarian tumor 
samples either untreated or after carboplatin (50 mg/kg) treatment in vivo. H&E stained images were acquired under 40x magnification. 
C. Nuclear texture parameter analysis in xenografts with and without carboplatin treatment on Day 2. Data for each spot represents the 
average value of each single sample with the number of nuclei analysed per sample ranging from 16 to 213 (average 103). Mann-Whitney 
U test (2-tailed); *P<0.05, **P<0.01 D. Changes in chromatin patterns in PEO1 cells after cisplatin (6uM) or radiation (6Gy) treatment 
for 24h, and in OV1002 xenografts in vivo after carboplatin treatment, measured by parameters describing nuclear texture using Image J. 
The (+) and (-) represent positive and negative correlations with each type of chromatin pattern, respectively, and the arrows indicate the 
direction of change for each pattern.
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to controls, with the most significant effects of single-
dose carboplatin typically seen two days after treatment 
(entropy and IDM p=0.034 and 0.008, respectively; Figure 
2C), indicating that chromatin pattern changes occur after 
platinum treatment in vivo and in vitro (Figure 2D).
HDACs are differentially expressed in platinum-
resistant cell lines
It has previously been shown that HDAC1, HDAC3, 
and HDAC4 might be associated with resistance to 
chemotherapy and poor prognosis in cancer patients 
[32 - 34]. To investigate whether HDACs are involved 
in DNA damage-based treatment, we measured protein 
expression of HDAC class I (HDAC1, 2, 3, and 8) and 
IIA (HDAC4) members in PEO1 and PEO4 cells 24h after 
cisplatin treatment. The PE04 cell line was derived from 
the same patient as the PE01 cell line but after resistance 
had developed [30]. Since changes in nuclear texture after 
cisplatin treatment were most pronounced at 24 h, we 
speculated that HDACs would similarly show maximal 
changes at this time point. HDAC2 expression was 
increased approximately 1.5 fold in cisplatin-treated PEO1 
cells, but not in PE04 cells, compared to controls at 24 h. 
Expression of HDACs 1, 3, 4 and 8 were unchanged in both 
cell lines after 24h (data not shown). This suggests that 
HDAC2 might be a cisplatin response biomarker in vitro, 
at least in sensitive cells. HP1 heterochromatin isoforms 
were also measured after cisplatin treatment (Figure 3A). 
Two HP1 isoforms (HP1α and HP1β) increased by about 
Figure 3. Expression of HDAC2 and heterochromatin proteins after cisplatin incubation. A. Western blots for HDAC2, 
HP1α, HP1β, and HP1γ in PEO1 and PEO4 cells with or without cisplatin treatment (6 uM, 24h). Membranes were probed with the 
indicated antibodies, and tubulin was used as a loading control. B. HDAC2 and HP1 protein expression detected by immunofluorescence. 
Cells were seeded on cover slips and fixed as described in the Materials and Methods in PEO1 cells after cisplatin treatment for 6h and 24h. 
Alexa488 (green channel) and DAPI (blue channel) were used to stain target proteins and the nuclei, respectively. Images were taken using 
a confocal microscope. C. Expression of HDAC2, HP1α, HP1β, and HP1γ mRNA in PEO1 cells measured by RT-PCR as described in the 
Materials and Methods. Relative expression of the target gene was calculated as the average ΔCt and normalized to that of the housekeeping 
gene β-actin. Results are as presented as mean ±SD from biological triplicates. *p<0.05, **p<0.01 (Student’s t-test).
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30% and 70%, respectively, but only in PEO1 cells after 24 
h cisplatin treatment, while HP1γ protein remained static.
To visualise and confirm these observations, 
immunofluorescence (IF) was performed on PEO1 and 
PEO4 cells with or without cisplatin treatment using 
antibodies targeting HDAC2, HP1α, HP1β, and HP1γ 
(Figure 3B). As expected, expression of HDAC2 increased 
24 h after cisplatin treatment, and HP1 proteins gradually 
increased over 24 h of cisplatin treatment in PEO1 cells 
(Figure 3B). Again no changes were observed in PEO4 
cells (data not shown). The IF images confirmed nuclear 
localisation of these targets.
Since HDAC2 and HP1 protein expression changed 
after cisplatin treatment in PEO1 cells, we next measured 
mRNA expression. Transcription of HDAC2, HP1α, HP1β, 
and HP1γ were all significantly elevated by cisplatin 
treatment (p<0.05) after 24 h in PEO1 cells (Figure 3C), 
mirroring the protein expression changes; however, mRNA 
levels remained unchanged in PEO4 cells (data not shown). 
The changes in HP1 expression suggest that the amount of 
heterochromatin increases after DNA-damaging treatment.
Profiling expression of HDAC and HP1 proteins 
in ovarian cancer xenograft models
We then examined HDAC and HP1 expression in 
the platinum-sensitive OV1002 and platinum-resistant 
HOX424 xenograft models [31]. HDAC2 and all three 
HP1 proteins were significantly increased in the sensitive 
model (OV1002) after carboplatin treatment, with the most 
significant changes (p<0.05) observed on day 7 (Figure 4). 
In the HOX424 model, expression of these proteins was 
similar between control and treated groups.
Time-dependent cellular DNA damage response 
induced by cisplatin in ovarian cancer cells
We next investigated several DNA damage response 
(DDR) pathway members (γH2AX, pBRCA1, ATM, 
pATM, ATR, and pATR) by western blotting (Figure 5). As 
expected, the DNA damage response proteins pBRCA1, 
γH2AX, pATM, and pATR participated in the response to 
cisplatin and were upregulated after treatment. pBRCA1 
expression increased after 24 h of cisplatin treatment 
in PEO1 cells, which persisted to 96 h, while γH2AX, 
pATM, and pATR increases occurred slightly later from 
48 h. ATM and ATR protein expression remained stable 
except for ATM reductions at 96 h.
Expression profiling of other HDAC family 
members, heterochromatin proteins, and DNA 
damage response proteins under HDAC2 
suppression
Given that HDAC2 expression showed the most 
pronounced changes in response to cisplatin, we examined 
Figure 4. Expression of HDAC2, HP1α, HP1β and HP1γ in the OV1002 and HOX424 ovarian xenograft tumor models 
on Day 7 after carboplatin treatment. The sample TMA was probed with the indicated antibodies and expression levels were 
quantified by AQUA analysis. Boxplots depict AQUA scores representing the expression of proteins. Data was compared between control 
group (red bar) and carboplatin-treated group (blue bar) within the platinum sensitive model (OV1002) and resistant model (HOX424), 
respectively. Man-Whitney analysis was performed and P values are indicated.
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the effect of HDAC2 knockdown by siRNA (Figure 
6A). HDAC2 knockdown was efficient (Supplementary 
Figure 1). Expression of HDAC3, HDAC4, and 
HDAC8 were not significantly affected by HDAC2 
knockdown. Interestingly, HDAC1 expression was mildly 
upregulated after HDAC2 knockdown, indicating a 
possible compensatory effect as previously reported [35 
- 37]. Since HDAC2 was implicated in heterochromatin 
formation, we further assessed HP isoform expression 
after HDAC2 knockdown (Figure 6A). There were 
minor changes in HP1 protein expression, with mild 
downregulation (20%) of HP1α on HDAC2 knockdown. 
With respect to DNA damage response protein expression, 
HDAC2 knockdown resulted in marked upregulation of 
γH2AX and downregulation of pBRCA1 (Figure 6A). 
In contrast, other DDR proteins (pATM, ATM, pATR, 
ATR, and Rad51; Figure 6A) were not obviously affected. 
This suggests that double-strand breaks accumulate and 
DNA repair might be suppressed on HDAC2 knockdown, 
although the upregulation of γH2AX might also indicate 
that the cells are undergoing apoptosis [38].
Characterisation of cellular responses to 
cisplatin treatment in ovarian cancer cells when 
HDAC2 is suppressed
We next investigated the potential role of HDAC2 in 
cisplatin response. PE01 cells were treated with cisplatin 
after HDAC2 knockdown (Figure 6B). HDAC2 was 
consistently upregulated at 24 h and downregulated at 
later time points in response to cisplatin without HDAC2 
knockdown. Unsurprisingly, the induction of double-
strand breaks (DSBs) indicated by γH2AX expression 
occurred as early as 6 h, while γH2AX expression 
increased after 24 h of cisplatin treatment in cells depleted 
of HDAC2 compared to cisplatin-treated or HDAC2 
knockdown groups. This accumulation diminished over 
72 h. As expected, pBRCA1, pATM, pATR, and Rad51 
participated in the DNA damage response triggered by 
cisplatin at certain time points (6h, 24h, 48h, and 24h) and 
were upregulated. In contrast, cisplatin reduced expression 
of these proteins in cells with HDAC2 knockdown from 
24h to 72h (Figure 6B).
Figure 5. Time-dependent expression of DNA damage response proteins in PEO1 cells. Cells were seeded and treated with 
or without cisplatin (6μM), and protein lysates were collected every 24h after treatment from 0h to 96h. Western blotting was performed to 
detect expression of pBRCA1, γH2AX, pATM, ATM, pATR, and ATR. Membranes were probed with the indicated antibodies, and tubulin 
was used as a loading control. Experiments were performed at least three times acquiring similar results. Blots from one representative 
experiment are shown.
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The cisplatin-resistant PEO4 cell line was next 
studied to further clarify the involvement of HDAC2 
during cisplatin-induced DNA damage responses 
(Supplementary Figure 2). There was little change 
in HDAC2 expression in PEO4 cells during cisplatin 
treatment, except for decreased expression at 72 h. 
In contrast to PEO1 cells, the cumulative effect of 
HDAC2 depletion and cisplatin treatment on γH2AX 
was not observed in PEO4 cells, although induction 
of DSBs was noted from 24 h in response to cisplatin 
alone. Additionally, pBRCA1, pATM, and RAD51 were 
upregulated by cisplatin treatment alone. Expression 
of these proteins was suppressed by HDAC2 depletion, 
although the pattern of expression over time was different 
to PEO1 cells.
Role of HDAC2 in γH2AX foci formation during 
cisplatin treatment
γH2AX foci at DNA damaged domains are 
indicative of inter-strand crosslinking by cisplatin [39]. 
The detection of ser139-phosphorylated γH2AX foci has 
been widely used to evaluate double-strand breaks (DSBs) 
[40]. Therefore, γH2AX foci were targeted and visualised 
using immunofluorescence microscopy (Figure 7). γH2AX 
foci were formed in PEO1 (Figure 7) and PE04 cells in 
response to cisplatin (Supplementary Figure 3). Similarly, 
HDAC2 knockdown resulted in γH2AX foci in both cell 
lines (Figure 7 and Supplementary Figure 3). There was 
a marked increase (number and intensity) in γH2AX 
foci in PEO1 cells treated with cisplatin after HDAC2 
Figure 6. The effect of siHDAC2 knockdown on expression of other HDAC family members, HP1s, and DNA damage 
response proteins by western blotting in PEO1 cells alone (A) and in the presence / absence of cisplatin (B). Protein was 
lysed after HDAC2 was knocked down after 72 h using reverse transfection. Non-transfection (control), mock, and siRNA negative control 
were used as controls. Membranes were probed with the indicated antibodies, and tubulin was used as a loading control. Experiments were 
performed at least three times acquiring similar results. Blots from one representative experiment are shown. In (B), cells were treated with 
cisplatin (6μM) after 72h incubation with mock (lane 1), siRNA negative control (lane 2), or HDAC2 siRNA duplexes (10pmol in 6mL, 
lane 3). Protein lysates were collected at 6h, 24h, 48h, and 72h after cisplatin treatment and analysed by western blotting of DNA damage 
response proteins; tubulin was used as loading control. Experiments were performed at least three time acquiring similar results. Blots from 
one representative experiment are shown.
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knockdown, which was less pronounced in PEO4 cells, 
similar to cisplatin alone (Supplementary Figure 3). Using 
a cut-point of five foci per cell as negative background, the 
number of foci-positive PEO1 cells significantly increased 
after cisplatin treatment, HDAC2 knockdown, and 
cisplatin treatment in HDAC2-depleted cells (p<0.05 and 
0.01 compared to cisplatin-treated and siRNA-transfected 
groups, respectively; Figure 7). In PE04 cells, cisplatin 
induced foci (p<0.001), while HDAC2 knockdown 
did not.
Cell fate determination by HDAC2 knockdown 
during cisplatin treatment
We assessed the effect of HDAC2 knockdown on 
cell fate with and without cisplatin treatment. Growth 
inhibition by cisplatin was concentration dependent 
manner in both control HDAC2 knockdown groups in 
PEO1 cells (Figure 8A). Cisplatin treatment alone induced 
significant S-phase arrest in PEO1 cells (+160%, p<0.001) 
and decreased the number of G1-phase cells (-30%; 
p<0.05) (Figure 8B). HDAC2 knockdown alone increased 
the S phase population (+120%, p<0.05). As expected, 
cisplatin treatment in HDAC2-depleted cells altered the 
cell cycle distribution in PEO1 cells, but in a different 
way: HDAC2 knockdown caused further S-phase arrest 
induced by cisplatin in PEO1 cell (+120%, p<0.05) and 
an additional reduction in G1 phase cells (-20%, p<0.001). 
In contrast, HDAC2 depletion seemed to reduce S-phase 
accumulation (-20%, p<0.001) and increase the G1-phase 
population (+140%, p<0.05) based on measurements of 
cisplatin treated cells without transfection.
We next analysed the effect of cisplatin and HDAC2 
knockdown on apoptosis (Figure 8C). Cisplatin induced 
early apoptosis (annexin V positive only) (p<0.001). 
HDAC2 knockdown caused both early and late apoptosis 
(p<0.001). Furthermore, HDAC2 depletion induced 
significant (especially early) apoptosis after cisplatin 
treatment (p<0.001).
Reversibility of HDAC inhibition on nuclear 
morphological changes during cisplatin 
treatment
To test if the nuclear structural changes were 
mediated by HDACs, then specifically HDAC2, 
we investigated whether the nuclear changes were 
reversible by applying either the broad-spectrum HDAC 
inhibitor trichostatin A (TSA) or HDAC2 siRNA in 
PEO1 cells. When PEO1 cells were treated with TSA, 
all five texture parameters were altered: angular second 
moment, correlation, and inverse difference moment 
Figure 7. Immunofluorescence for γH2AX foci in PEO1 cells. Cells were grown and treated as described before, and images were 
taken after 24 h treatment of cisplatin in cells with or without HDAC2 siRNA. Antibodies against H2AX phosphorylation at Ser 139 were 
used to probe cellular γH2AX foci (red channel), and DAPI was applied for nuclear staining (blue channel). A. Representative images from 
one experiment are shown. >100 cells in each group were included for one experiment, and three independent experiments were performed. 
B. Distribution of γH2AX foci / cell in PEO1 cells.
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increased, while entropy and contrast decreased (Figure 
9A). Decreased chromatin heterogeneity and contrast 
and increased homogeneity are consistent with HDAC 
inhibition relaxing the chromatin structure. With HDAC2 
siRNA (Figure 9B), comparable changes to TSA were 
observed.
DISCUSSION
Within this study, we show that comparable nuclear 
morphological changes occur in several ovarian tumor 
models (cell lines and xenografts) after treatment-induced 
cellular damage. Image analysis of nuclear texture has 
previously been used to differentiate between benign and 
malignant cancers [28], examine apoptotic cells [41], 
and study the condensation and distribution of chromatin 
in the nucleus in drug-sensitive and resistant cells [42]. 
In the present study, increased nuclear heterogeneity 
was assumed to indicate a transition from euchromatin 
to heterochromatin. Consistent with this, HP1 isoform 
expression increased after cisplatin treatment in vitro, 
which was accompanied by enhanced expression of 
HDAC2 at both the mRNA and protein levels. Studies 
in vivo using a patient-derived ovarian cancer xenograft 
model also showed elevated HDAC2 and HP1 isoform 
expression after chemotherapy.
As an essential component of heterochromatin, 
HP1 accumulates in response to UV or ionising radiation 
consistent with chromatin reorganisation [43]. We obtained 
a similar result, with enhanced heterochromatin formation 
following chemotherapy both in vivo and in vitro. HDAC2 
was upregulated after 24h of cisplatin treatment in 
vitro, with similar results seen in vivo in ovarian cancer 
xenografts. In line with its function as a regulator of 
condensed chromatin formation, HDAC2 expression 
changed consistent with the observed changes in nuclear 
texture and was a possible mediator of the DNA damage 
response. This alteration in chromatin pattern might 
also indicate that chemotherapy induces transcriptional 
silencing, perhaps as a form of cellular self-protection 
upon injury. There is evidence that HDAC-containing 
complexes including Mi-2/NuRD and/or Sin3/HDAC 
chromatin-modifying complex (containing HDAC1 and 
HDAC2) participate in nuclear reorganisation and gene 
repression during development [44]. Mi-2/NuRD and 
mSin3/HDAC co-repressor complexes are also necessary 
for pericentric heterochromatin assembly and chromosome 
segregation [45, 46].
There were time-dependent changes in the 
expression of DNA damage response proteins including 
pBRCA1, γH2AX, pATM, and pATR after cisplatin 
treatment in PEO1 cells. As a marker of double strand 
breaks, elevated γH2AX expression indicated activation 
of DSB repair pathways in response to cisplatin treatment 
in PEO1 cells; there is evidence to show that the tumor 
suppressor function of BRCA1 occurs via heterochromatin 
silencing, with increased levels of both heterochromatin 
and BRCA1 observed after DNA damage [47]. Our 
results are consistent with these findings, and suggest 
that chromatin remodelling by HDACs is involved in the 
Figure 8. The effect of HDAC2 knockdown on cell number (A), cell cycle distribution (B), and apoptosis (C) in PEO1 
cells. A SRB assay profile for growth inhibition of cisplatin on PEO1 cells with (green line) and without (blue line) HDAC2 knockdown. 
Cells were reverse transfected with HDAC2 siRNA, followed by treatment with cisplatin for 72h. Three controls were included as described 
before. B. Percentages of the populations selected in G0/1, S, G2/M phases of the cell cycle were detected by flow cytometry. Columns 
represent the mean percentage of triplicate independent samples. Error bars represent SD. The Brown-Forsythe test followed by Games-
Howell post-hoc test were performed to compare groups for each phase. C. The effect of HDAC2 knockdown on apoptosis in PEO1 cells 
using the annexin V assay is shown. Cell number percentages of the population selected with positive annexin V staining were detected 
by flow cytometry after cisplatin treatment for 72h, and data are separated into early and late apoptosis based on propidium Iodide (PI) 
signal. Columns represent the mean percentage of triplicate independent samples. Error bars represent SD. One-way ANOVA analysis was 
performed to compare data among groups, and the Tukey HSD pot HOC test was used to compare groups.
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cellular response to DNA damage therapy such as double 
strand break and DNA repair.
HDACs are associated with malignancy and poor 
clinical outcomes in multiple cancer types [13, 17]. 
Roles for HDAC2 have been identified in a variety of 
malignancies. In colon cancer cells, HDAC2 expression 
has been associated with chemoresistance to genotoxic 
stress [48]. In neuroblastoma, HDAC2 has been show 
to act with N-MYC to reduce TP53INP1 expression 
which influences p53 phosphorylation at serine 46, with 
subsequent effects on cell proliferation and survival [49]. 
In leukemia, HDAC2 silencing induces modulation of 
gene expression leading to strong transcriptional activation 
[50] while in lung cancer, HDAC2 has been proposed to 
exert an effect on survival by sustaining Mdm2-survivin 
levels [51]. A number of studies have demonstrated 
efficacy of combined HDAC inhibitor and cytotoxic 
chemotherapy. The HDAC inhibitor romidepsin (FK228), 
approved for phase I and II trials, enhances the cytotoxic 
effects of cisplatin by reducing cell growth and inducing 
more DNA damage-induced cell death in vitro and in vivo 
[52]. Since HDAC2 in particular was associated with 
Figure 9. Changes in nuclear texture features in PEO1 cells treated with TSA (A) or transfected with HDAC2 siRNA 
before cisplatin treatment (B). A. PEO1 cells were grown on coverslips and treated with TSA (250nM) for 24h, and nuclei were stained 
with DAPI for visualisation using a fluorescence microscope. At least 100 nuclei were included in one experiment. Nuclear texture was 
analysed by measuring five texture parameters (angular second moment, correlation, entropy, inverse different moment, and contrast) in 
Image J software. Data are presented as the average change (%) in TSA treated group for each parameter over control group. B. PEO1 cells 
were grown on coverslips, transfected with HDAC2 siRNA for 72h, and treated with cisplatin (6μM) for a further 24h. Nuclei were stained 
with DAPI for visualisation using fluorescence microscopy. At least 100 nuclei were included in each group in one experiment. Nuclear 
texture was analysed by measuring five texture parameters (angular second moment, correlation, entropy, inverse different moment, and 
contrast) using Image J.
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early responses to cisplatin in our cell culture studies, cell 
growth was evaluated in response to HDAC2 knockdown. 
HDAC2 depletion reduced the IC50 of cisplatin in PEO1 
cells, suggesting that HDAC2 loss enhances the effect of 
cisplatin treatment. Repression of cell growth in chemo-
sensitive PEO1 cells by cisplatin after HDAC2 silencing 
appeared to be due to accumulated S-phase arrest and 
apoptosis.
Cell cycle progression blockade has been reported 
to occur as a result of checkpoint activation during DNA 
damage-based therapy, and at least one checkpoint protein, 
Chk1, is upregulated during intra-S-phase accumulation 
by affecting chromatin formation and interfering with the 
initiation and elongation of DNA replication [53]. It is 
feasible that HDAC2 interacts with checkpoint proteins 
to prevent DNA replication by condensing the chromatin 
in self-protection, and triggers apoptosis via distinct 
pathways in platinum sensitive and resistant cells. Several 
mechanisms have been suggested to explain HDAC 
inhibitor-induced apoptosis, such as altered transcription 
and DDR and DNA damage repair [54-56]. The early 
upregulation (after 24 h) of HDAC2 in sensitive cells 
may suggest that HDAC2 is acting as a sensor of DNA 
damage and a trigger of downstream DDR events (such 
as activation of ATM, ATR, and BRCA1) and chromatin 
remodelling, followed by histone hyperacetylation to relax 
the chromatin structure and facilitate recruitment of more 
DDR mediators to the damaged site.
DSBs (measured by γH2AX) accumulated after 24 h 
of cisplatin treatment in HDAC2-depleted PEO1 cells, but 
not PEO4 cells. High γH2AX expression has previously 
been associated with cell viability and apoptosis in ovarian 
cancer [57], which was attributed to the cell type tested 
and time after damage. H2AX activation has also been 
noted a number of days after treatment with an HDAC 
inhibitor, suggesting that increased γH2AX expression 
precedes cancer cell death [58]. Suppression of DDR 
activation (as evidenced by pATM, pATR, pBRCA1, and 
RAD51 expression) after HDAC2 knockdown strongly 
suggests that HDAC2 is involved in responses to DNA 
damage-based treatment. The differences between PEO1 
and PEO4 cells in DSB accumulation and time of pathway 
activation or suppression is consistent with the observed 
differences in cell cycle progression, and also might be 
due their differences in cisplatin sensitivity. The two major 
pathways of DSB repair, non-homologous end joining 
(NHEJ) and homologous recombination (HR), appear to 
compensate for each other [59], and their balance might 
be disrupted by the known BRCA2 deficiency in PEO1 
and secondary mutation to restore BRCA2 in PE04 [60]. 
This might influence the dominant mechanism of repair 
in the two cell lines and cause differences in the observed 
functional activity of the measured DNA damage response 
proteins after cisplatin treatment.
Together, these results suggest that chromatin 
remodelling caused by increased HDAC2 expression 
might be an early cellular event (within 24 h) in response 
to DNA damage. We postulate that, in sensitive tumors, 
early alterations in chromatin induced by chemotherapy 
and mediated by histone deacetylation are a form of 
cellular self-defence to injury by repressing transcription, 
initiating chemotherapy-triggered DDR, and promoting 
survival. This is followed by a change to a relaxed 
chromatin conformation by histone hyperacetylation, such 
as via H3k56Ac and H4k16Ac, to provide accessibility 
of DNA to downstream proteins at damaged sites [61 - 
63]. However, resistant tumors behave differently in terms 
of their response to DNA damage to chemotherapy; this 
might be due to their initial chromatin environment or due 
to other changes in the components of the DDR response 
pathways in which HDACs participate. In one study, 
HDAC1/2-associated immediate histone hypoacetylation 
occurred after laser microirradiation of a human 
osteosarcoma cell line to promote NHEJ, which was 
followed by hypoacetylation to enhance HR and guard 
genome integrity [64], supporting our hypothesis. Linkage 
between HDAC2 modulation and H4k16 acetylation has 
been shown in breast cancer [65].
By identifying the detailed roles that HDACs play 
in DNA damage responses by remodelling chromatin, we 
hope to better understand the molecular processes that 
underpin nuclear structure and identify novel mechanisms 
that control responses to chemotherapy.
MATERIALS AND METHODS
Cell culture
Cisplatin-sensitive PE01 and cisplatin-resistant 
PE04 ovarian cancer cell lines derived in our laboratory 
[30] were cultured as monolayers in RPMI 1640 
supplemented with 10% heat-inactivated foetal calf serum 
(FCS) and penicillin/streptomycin (100 IU/mL) in 5% CO
2
 
at 37°C.
Ovarian cancer xenografts
Two ovarian cancer patient-derived xenograft 
models were previously established in our laboratory: 
OV1002 and HOX424 [66]. Female adult CD-1 nude 
mice housed in individually ventilated cages were treated 
with carboplatin (50 mg/kg i.p.) on day 0, and tumor 
samples were collected on days 0, 1, 4, 7, and 14 after 
treatment. Tumors were formalin fixed and paraffin 
embedded (FFPE). The OV1002 xenograft model was 
markedly more sensitive to carboplatin treatment than the 
HOX424 model [31]. Xenograft studies were undertaken 
under a UK Home Office Project Licence in accordance 
with the Animals (Scientific Procedures) Act 1986, and 
the University of Edinburgh Animal Ethics Committee 
approved the study protocol.
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Nuclear texture analysis
Confocal microscopy images were obtained using 
a Nikon A1R Confocal Microscope (Nikon Corporation, 
Tokyo, Japan) and images were viewed in NIS Viewer 
(Nikon). Cells were grown on chamber slides for the 
periods specified and fixed in 10% formalin in PBS for 10 
min. After washing three times with PBS-0.05% Tween 
20, slides were counterstained with anti-fade reagent with 
DAPI (Invitrogen, P36931; Thermo Fisher Scientific, 
Waltham, MA). Nuclear texture was analysed using Image 
J software. Briefly, after input of 8-bit images, fully focused 
areas containing tumor cells were marked as regions of 
interest (ROI) and individual nuclei selected. Nucleus 
counter and GLCM (grey-level co-occurrence matrix) [67] 
manager plugins were performed on each image and five 
parameters associated with texture obtained: correlation, 
contrast, angular second moment (ASM), inverse different 
moment (IDM), and entropy. GLCM [67, 68] is a second-
order texture calculation that considers the distance and 
angle relationship between two-pixel groups in the original 
greyscale image under the same intensity of grey pixels 
within a defined area. Texture features were regarded as 
positively or negatively associated with chromatin patterns 
(homogeneity, heterogeneity, and contrast) as previously 
described [28, 29].
siRNA knockdown of HDAC2
Loss of HDAC2 function was achieved with 
siRNA transfection of cells in 60mm cell culture dishes 
according to the manufacturer’s instructions. Briefly, 
siRNA duplex-Lipofectamine™ RNAiMAX complexes 
(Life Technologies, Thermo Fisher Scientific) were 
prepared as follows. 10-100 pmol siRNA duplex 
was diluted in 500μl Opti-MEM® I Medium (Life 
Technologies) without serum in each cell culture 
dish and mixed gently. The duplex sequences were: 
GACAAACCAGAACACUCCAGAAUAU and 
AUAUUCUGGAGUGUUCUGGUUUGUC. A negative 
scrambled stealth siRNA duplex with similar GC content 
(low GC duplex) to the target was used as control. 0.8 
μl Lipofectamine™ RNAiMAX was added to each 
dish containing diluted siRNAs and incubated at room 
temperature for 20 min. After incubation, cells were 
diluted in complete growth medium without antibiotics at 
700,000 – 800,000 cells/5mL to ensure a cell density of 
30-50% 24h after seeding, and 5 mL was added to each 
well. Controls were untransfected (no transfection agents), 
mock (only Lipofectamine™ RNAiMAX mixture), and 
negative control (random RNAi duplex). The cells and the 
complexes were incubated for 24-120 h at 37ºC in full 
serum without antibiotics. For drug treatment, cisplatin 
was added after 48 h of transfection and cells were 
collected after several time points as indicated.
Protein extraction from mammalian cell lines
Cultured cells were washed in cold PBS and lysed 
by scraping in ice-cold isotonic lysis buffer (50mM Tris-
HCl (pH7.5), 5mM EGTA (pH 8.5), 150mM NaCl, 1% 
Triton X-100) supplemented with aprotinin (10 μg/mL) 
and a cOmpleteTM Protease Inhibitor Cocktail Tablet 
(Roche, 11836153001) for 30 min on ice. Lysates were 
centrifuged for 6 min at 13,000 × g and the supernatant 
stored at -70°C. Protein concentrations were determined 
using the bicinchoninic acid (BCA) assay (Sigma, BCA-1; 
Sigma-Aldrich, St. Louis, MO).
Western blotting
After SDS-PAGE using 10% polyacrylamide gels, 
resolved proteins were transferred to nitrocellulose 
membranes at 30V, 4°C overnight. After transfer, 
membranes were rinsed in PBST and blocked with Li-
Cor Odyssey Blocking Buffer (LI-COR Biosciences, 
Lincoln, NE; diluted 50:50 in PBS) for 1h at room 
temperature before probing overnight at 4°C with 
the appropriate primary antibody in Li-Cor Odyssey 
Blocking Buffer. Primary antibodies were rabbit and 
obtained from Cell Signaling Technology (Beverly, MA) 
and used at 1:1000 unless otherwise indicated: anti-HP1 
alpha (#2623), anti-HP1 beta (Abcam/ab10478), anti-
HP1 gamma (#2619), anti-HDAC1 (mouse, #5356), 
anti-HDAC2 (#2540), anti-HDAC3 (Abcam (Cambridge, 
UK) ab32369), anti-HDAC4 (Abcam ab32534), anti-
HDAC8 (Abcam ab39664), anti-AMT (1:750 Abcam 
ab67998, mouse), anti-pATM (Ser1981; #4526), anti-
ATR (Abcam ab2905), anti-pATR (Ser428; #2853), 
anti-pBRCA1(Ser1524; #9009), anti-γH2AX (#2577), 
anti-Rad51 (H-92) (Santa Cruz Biotechnology, Dallas, 
TX; sc-8349), anti-α-tubulin (1:6000 Mouse Abcam 
ab7291), anti-β-tubulin (1:6000 Abcam ab6046), anti-
GAPDH (1:8000 Mouse Abcam ab8245). Membranes 
were washed with PBS-Tween20 before incubation with 
fluorescently-labelled secondary antibodies diluted in 
Odyssey Blocking Buffer (50:50 in PBST) at 1:10,000 
dilution. Mouse-derived primary antibodies were 
detected using an anti-mouse fluorescently-labelled 
secondary antibody (680nm wavelength), whilst rabbit-
derived primary antibodies were detected using an anti-
rabbit fluorescently-labelled secondary antibody (800nm 
wavelength) (45 min incubation). By combining a mouse 
primary with a rabbit primary along with their respective 
secondary antibodies, dual-labelled blots were obtained. 
Membranes were scanned on the Li-Cor Odyssey 
scanner, and the fluorescence value (integrated intensity, 
I.I.) corresponded to protein expression levels. Alpha-
tubulin (Mouse Abcam ab7291) was used as loading 
control.
Oncotarget13www.impactjournals.com/oncotarget
RNA preparation and real time polymerase 
chain reaction (RT-PCR)
Total RNA was extracted from cultured cells 
using the Qiagen Mini RNeasy Kit according to the 
manufacturer’s instructions (Qiagen, Limburg, NL). 
The concentration and quality of RNA were assessed by 
NanoDrop. 1μg of total RNA from each individual sample 
was reverse transcribed using the QuantiTect Reverse 
Transcription kit (Qiagen) following the manufacturer’s 
instructions to produce 20μL of cDNA, which was 
quantified using Rotorgene (Corbett Research, San 
Francisco, CA) and the QuantiTect SYBR Green system 
(Qiagen) following the manufacturers’ instructions. For 
PCR, a 13-fold dilution of the cDNA mixture (10-fold 
dilution for standard curve) and a 10-fold dilution of 
primers for HDAC8 and β-actin (Qiagen) were used. A 
15ul mixture of 7.5μl 2xQuantiTect SYBR Green iMaster 
Mix, 1.5 μL primer mix (0.3 μM), 2.5mM of MgCl
2
, and 
1.5 μL cDNA was prepared in RNase-free water for the 
PCR reactions. PCR was performed as follows: 95°C for 
15min; 45 cycles at 94°C for 15s, 56°C for 30s, 72°C for 
30s; 72°C for 5min followed by melting from 55°C to 
95°C at 0.2°C/s.
Immunofluorescence (IF) on xenografts
4μm TMA sections were deparaffinised in xylene for 
5 min and rehydrated through graded ethanol. For antigen 
retrieval, sections were treated with 0.15mM sodium 
citrate, pH 6.0 or Tris-EDTA, pH9.0 using a microwave 
pressure cooker for 5 min. Sections were rinsed in 0.05% 
PBST, blocked in 3% hydrogen peroxide and serum-
free protein block (Dako, Glostrup, Denmark; #X0909), 
10 min each. After blocking, slides were incubated with 
primary antibodies diluted in second primary antibody 
(mouse anti-cytokeratin, Invitrogen, #18-0132) in Dako 
antibody diluents (1:25) for 1h at room temperature or 
overnight at 4°C. Primary antibodies were rabbit from 
Cell Signaling unless otherwise indicated: anti-HP1 alpha 
(#2623; 1:100 dilution), anti-HP1 beta (Abcam ab10478; 
1:150), anti-HP1 gamma (#2619; 1:400 dilution), anti-
HDAC1 (mouse #5356; 1:25 dilution), anti-HDAC2 
(#2540; 1/100 dilution), anti-HDAC3 (Abcam ab32369; 
1/100 dilution), anti-HDAC4 (Abcam/ab32534; 1/100 
dilution) and anti-HDAC8 (Abcam/ab39664; 1/100 
dilution). Sections were rinsed in 0.05% PBST three 
times followed by incubation with secondary antibodies 
for 1 h at room temperature with a 1:25 dilution of goat-
anti-mouse Alexa 555 antibody (Invitrogen, #A21422). 
After rinsing, sections were incubated with target signal 
amplification diluents and Cy5 tyramide at 1:50 in the dark 
for 10 min at room temperature for target visualisation. 
Finally, slides were rinsed, dehydrated in 80% ethanol for 
1 min, air dried in the dark, and counterstained and cover-
slipped using Prolong Gold anti-fade reagent with DAPI 
(Invitrogen, P36931).
IF was analysed using the Automated QUantitative 
Analysis (AQUA) system (HistoRx, New Haven, CT) as 
previously described [69]. For each immunofluorescence 
image, AQUAnalysis software evaluated the quantity (in 
AQUA units=Au) of target protein expression (through 
Cy-5-tyramide) within the cytoplasm (identified by 
cytokeratin) and nuclei (DAPI). Images were examined 
to exclude imaging faults and normal tissue, thus target 
protein expression was scored only in invasive cancers. 
Cores containing <5% epithelium were automatically 
excluded to ensure tissues were representative of tumors 
[70]. The final normalised AQUA score detecting the 
fluorescence correlates with the expression level of target 
protein.
Sulforhodamine B cell proliferation assay
Cells were harvested in log phase, counted using 
a haemocytometer, and optimal initial numbers of cells 
in 200 uL per well were seeded into 96 well cell culture 
plates for 72h. After 0 to 6 days incubation with small 
molecules, cells were fixed in 25% cold trichloroacetic 
acid (50uL/well), and incubated for 1 h at 4°C. Plates 
were washed, air-dried, and stained with sulforhodamine 
B dye (0.4% solution in 1% acetic acid, 50 μl/well) for 30 
min. After washing with 1% acetic acid, plates were dried. 
100uL Tris buffer (10mM, pH 10.5) was added into each 
well 1 h prior to reading and the optical density (OD) was 
recorded using a Biohit BP800 Microplate reader (Biohit, 
Helsinki, Finland) at 540 nm.
Cell cycle analysis
Cells were harvested and plated as described for 
western blotting. At the time points indicated, cells 
were trypsinised and transferred to 5 mL BD Falcon 
tubes (BD Biosciences). Citrate buffer (trisodium citrate 
(301287F, BDH Laboratory Supplies, Poole, UK), 
121mg Tris Base (T1378, Sigma), 1044 mg spermine 
tetrahydrochloride (S2876, Sigma) and 2mL Nonidet 
NP40 (N3516, Sigma) in 2000mL distilled water, pH7.6) 
was added after centrifugation. The following solutions 
were added in sequence prior to analysis: 450uL solution 
A (0.003% trypsin type IX-S (T0303, Sigma) in citrate 
buffer, pH7.6) for 2 min, solution B (0.05% trypsin 
inhibitor (T9253, Sigma) and 0.01% RNAse A (R4875, 
Sigma) in citrate buffer pH7.6) for 10 min, and solution 
C (0.0416% propidium iodide (81845, Sigma) and 0.1% 
spermine tetrahydrochloride (S2876, Sigma) in 500 mL 
citrate buffer pH7.6) for 10 min in the dark. Apoptosis was 
detected at 24 h using the TACS Annexin V-FITC Kits (R 
&D Systems) according to the manufacturer’s protocol. 
Flow cytometry was performed using a BD FACSAriaII 
SORP (Becton Dickinson, Franklin Lakes, NJ). BD 
FACSDiva software (Becton Dickinson, Version 6.1.2) 
was used for instrument control and Flowjo software 
(Version 7.6.5) for Data analysis.
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Quantitative analysis of γH2AX foci formation 
in cells
Cells were grown and stained as described above 
using anti-phospho-histone H2AX (ser139, γH2AX; 
Millipore 05-636) primary antibody. After mounting 
with DAPI and air-drying, cells were visualised with 
a BriteMAC or MacRd microscope. Nuclear images 
were taken with IPLab software with single filters for 
each channel and the same exposure for each set of 
experiments. For each slide, over 100 nuclei were counted 
for foci formation. The number of γH2AX foci in each 
nucleus was counted by the PZ Foci EZ plugin in ImageJ 
as described (available at www.pzfociez.com). Briefly, 
a nuclear mask defining ROIs was first created for each 
channel, and then the foci number was automatically 
counted in the channel within the defined ROI.
Statistical analysis
Student’s t-test was used to compare two 
independent samples. One-way ANOVA followed by the 
Tukey test was for multiple comparisons of groups with 
equal variance. Pearson correlations were performed for 
IF correlations. The Wilcoxon signed-rank test was used 
to compare target protein expression differences between 
the pre- and post-treatment samples from patients, and the 
Mann-Whitney test was performed to compare xenograft 
data. All data were analysed using GraphPad Prism 
(GraphPad Software Inc., La Jolla, CA), and a p-value 
<0.05 was considered statistically significant.
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